Catalog No.
Product Name
Application
Product Information
Citations
-
PKA activator
Dibutyryl-cAMP is a cell-permeable PKA activator by mimicing the action of endogenous cAMP.- Bahar Sarikamis Johnson, .et al. , Metab Brain Dis, 2025, Oct 29;40(8):300 PMID: 41160319
- Nilufer Ercin, .et al. , Mol Neurobiol, 2025, Sep;62(9):11030-11046 PMID: 40257688
-
PKA inhibitor
H 89 dihydrochloride is a cell-permeable, selective, reversible, ATP-competitive and potent inhibitor of protein kinase.- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Guo Q, .et al. , Biomed Pharmacother, 2020, Mar;123:109812 PMID: 31945696
- Y Kaibori, .et al. , the FASEB Journal, 2019, Jan 22:fj201801519RR PMID: 30668924
-
Akt inhibitor
A-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Kobayashi T, .et al. , Biochem Biophys Res Commun, 2018, Jan 1;495(1):1468-1475 PMID: 29196261
- Lin Xu, .et al. , Biochem Biophys Res Commun, 2016, Apr 15;472(4):662-8 PMID: 26920060
- Zou Y, .et al. , Biochem Biophys Res Commun, 2016, Aug 12;477(1):1-8 PMID: 26970307
-
PKA inhibitor
PKI 14-22 amide, myristoylated is a useful heat stable cAMP-dependent protein kinase inhibitor. This is often used to study PKA in cellular systems in-vitro.- Dao-Lai Zhang, .et al. , eLife, 2018, 7: e33432 PMID: 29393851
-
PKA, PKG, Casein Kinase I and II inhibitor
A-3 Hydrochloride is an inhibitor of PKA (cAMP-dependent protein kinase, Ki=4.3μM) and cGMP-dependent protein kinase, Ki=3.8μM, PKC (protein kinase C, Ki=47μM), casein kinase I and II, and MLCK (myosin light chain kinase) ( Ki=7.4μM). -
MAPKAP-K2 (MK-2) inhibitor
MK-2 Inhibitor III (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM. -
PKs inhibitor
HA-100 is an isoquinoline compound with an added piperazinylsulfonyl group that acts as an inhibitor of protein kinases (PKs), including PKA, PKC, and PKG (IC50 = 8, 12, and 4 μM, respectively). -
protein kinase A activator
8-Bromo-cAMP is a cell perbeable cyclic AMP (cAMP) analog and a PKA activator. -
PKA-selective activator
6-Bnz-cAMP is a PKA-selective activator. It regulates the PKA dependent signaling pathways. -
reversible PKA inhibitor
Rp-cAMPS is a cell-permeable and reversible inhibitor of PKA (protein kinase A) (Ki = 11 uM). Rp-cAMPS is resistant to hydrolysis by phosphodiesterases and is noncompetitive with respect to ATP. -
PKG/PKA inhibitor
cGMP Dependent Kinase Inhibitor Peptid is a specific cGKI (cyclic GMP-dependent protein kinase) inhibitor. Data indicates that it does not block cyclic GMP-dependent protein kinase phosphorylation of intact histones and has been used to study Plasmodium falciparum. - Synaptamide is a potent mediator for neurogenic differentiation of NSCs acting through PKA/CREB activation.
-
protein kinase A inhibitor
Warangalone is a prenylated isoflavone from the insecticidal plant Derris scandens that acts as a powerful inhibitor of protein kinase A. -
PKA activator
Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC50 of 6.5 nM and Kd of 8 nM in Trypanosoma brucei. Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite activity. -
PKA inhibitor
PKA inhibitor fragment (6-22) amide is a synthetic peptide that acts as a protein kinase inhibitor. -
Akt inhibitor
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively, little activity outside the AGC kinase family. -
PKA Inhibitor
HA-1004 hydrochloride is a selective inhibitor of protein kinase A (PKA), known for its ability to inhibit lipolysis and promote vascular relaxation. In addition to its PKA inhibition, HA-1004 also functions as a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein synthesis, impacting smooth muscle and second messenger pathways. This compound serves as a vasodilator, effective in inhibiting the contraction of rabbit aortic strips, and can also antagonize ERK and tyrosine hydroxylase phosphorylation in morphine abstinence models. -
PKA Inhibitor
HA-1004 dihydrochloride is a selective inhibitor of protein kinase A (PKA), demonstrating significant inhibition of lipolysis and induction of vascular relaxation. Additionally, it acts as a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein kinase, playing a crucial role in regulating smooth muscle activity and second messenger pathways. This compound serves as a vasodilator, effectively inhibiting contraction in rabbit aortic strips, and also antagonizes ERK and tyrosine hydroxylase phosphorylation in models of morphine abstinence. -
LIM/ROCK/PKA Inhibitor
LX7101 monohydrochloride is a potent inhibitor of LIM-kinase, ROCK, and PKA, exhibiting IC50 values of 24 nM, 1.6 nM, 10 nM, and <1 nM for LIMK1, LIMK2, ROCK2, and PKA, respectively. This compound demonstrates significant selectivity for LIMK2 with an IC50 of 4.3 nM in contrast to 32 nM for LIMK1 at 2 μM ATP. LX7101 monohydrochloride is valuable for research into ocular hypertension and associated glaucoma, providing insights into potential therapeutic strategies targeting these pathways. -
PKC/PKA Inhibitor
MDL 27032 is a selective active site-directed inhibitor of protein kinase C (PKC) and cAMP-dependent protein kinase (PKA), exhibiting Ki values of 24 μM and 14.3 μM, respectively. This compound demonstrates significant vasodilatory effects by relaxing vascular smooth muscle. Its properties make MDL 27032 a valuable tool for investigating PKC and PKA-mediated pathways in cardiovascular research and other related studies. -
PKA I/II Antagonist
Rp-cAMPS sodium salt is a selective antagonist of protein kinase A (PKA) I and II, acting through competitive inhibition of cAMP-induced activation, with inhibition constants (Kis) of 12.5 µM and 4.5 µM, respectively. This stable cAMP analog is resistant to phosphodiesterase hydrolysis, making it an essential tool for investigating PKA signaling pathways. Rp-cAMPS sodium salt is widely utilized in cellular and biochemical research applications where modulation of PKA activity is required. -
PKA Activator
8-CPT-Cyclic AMP sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA), crucial for regulating various cellular processes. This compound also exhibits potent inhibition of cyclic GMP-specific phosphodiesterase (PDE VA) with an IC50 of 0.9 μM, as well as inhibiting PDE III and PDE IV. Additionally, 8-CPT-Cyclic AMP sodium acts as a strong activator of exchange protein directly activated by cyclic AMP (Epac), making it valuable for studying signaling pathways and cellular responses related to PKA and Epac activation in biochemical research. -
PKA Substrate
Kemptide is a synthetic heptapeptide that serves as a specific substrate for cyclic AMP-dependent protein kinase (PKA). By mimicking natural substrates, Kemptide facilitates the study of PKA activity, making it a valuable tool for researchers investigating signal transduction pathways and cellular responses mediated by cAMP. Its use in biochemical assays can help elucidate the roles of PKA in various physiological processes and disease states. -
CREB/PKA Agonist
CW 008 is a selective agonist of the cAMP/PKA/CREB signaling pathway. This pyrazole-pyridine derivative is known to stimulate osteoblast differentiation in human mesenchymal stem cells and enhance bone formation in ovariectomized mouse models. Additionally, CW 008 exhibits potential as a stem cell differentiating agent and suppresses leptin secretion, further contributing to its role in osteogenesis research. -
PKA I/PKA II Activator
Sp-cAMPS sodium salt is a potent activator of both cAMP-dependent protein kinase A (PKA I and PKA II). It serves as a valuable tool for investigating PKA signaling pathways due to its ability to enhance cAMP levels. Additionally, Sp-cAMPS sodium salt acts as a competitive inhibitor of phosphodiesterase 3A (PDE3A) with a Ki value of 47.6 µM, and it interacts with the PDE10 GAF domain, exhibiting an EC50 of 40 µM. This reagent is useful for research applications in cellular signaling and pharmacology. -
PKA Inhibitor
Rp-8-Br-cAMPS sodium is a selective inhibitor of Protein Kinase A (PKA) that functions by occupying the cAMP binding sites on the regulatory subunits of PKA type I. This prevents the dissociation and activation of PKA, making it a valuable tool for studying signaling pathways dependent on PKA. Research applications include investigations into tumor biology, retrovirus-induced immune deficiencies, and the regulation of insulin secretion. -
PKA Inhibitor
H-8 dihydrochloride is a reversible, cell-permeable inhibitor of protein kinase A (PKA) that operates through an ATP-competitive mechanism. It effectively modulates PKA activity, making it a valuable tool for investigating cellular signaling pathways. This compound is widely utilized in cancer research and studies focused on metabolic disorders, allowing researchers to elucidate the roles of PKA in various biological contexts. -
PKA Agonist
Sp-8-Br-cAMPS sodium is a potent protein kinase A (PKA) agonist, exhibiting an EC50 of 360 nM. This cAMP analog effectively activates PKA, leading to significant biological effects such as the inhibition of T cell proliferation and modulation of the hemocyte non-self response in Lepidoptera larvae. It serves as a valuable tool for investigating PKA-related signaling pathways and immune responses in various biological contexts. -
PKA I/PKA II Activator
Sp-cAMPS is a cAMP analog that functions as a potent activator of protein kinase A (PKA) I and PKA II. Its ability to enhance PKA activity makes it a valuable tool for studying cAMP signaling pathways. Additionally, Sp-cAMPS acts as a competitive inhibitor of phosphodiesterase 3A (PDE3A) with a Ki value of 47.6 µM and binds to the GAF domain of PDE10 with an EC50 of 40 µM, further extending its utility in biochemical research applications. -
PKA-RII Disruptor
STAD 2 is a potent and selective disruptor of protein kinase A regulatory subunit type II (PKA-RII), exhibiting a dissociation constant (Kd) of 6.2 nM. It specifically interferes with the interactions between PKA and A-kinase anchoring proteins (AKAP) in an isoform-selective manner. Additionally, STAD 2 demonstrates antimalarial activity through a mechanism that is independent of PKA, making it a valuable tool for research into PKA-related signaling pathways and malaria therapeutics. -
PKA Inhibitor
PKI (14-24)amide TFA is a potent inhibitor of protein kinase A (PKA) that effectively blocks cyclic AMP-dependent protein kinase activity in various cellular contexts. This compound demonstrates significant inhibitory action, making it valuable for studies involving PKA-related signaling pathways. Its utilization in research can provide insights into the molecular mechanisms of PKA-mediated processes in health and disease. -
PKA Inhibitor
PKI (14-24)amide is a potent inhibitor of Protein Kinase A (PKA), effectively disrupting the activity of cyclic AMP-dependent protein kinase. This compound has been shown to strongly inhibit PKA activity in cell homogenates, making it a valuable tool for studying PKA-related signaling pathways and their biological implications. Its application in research can facilitate investigations into cellular processes regulated by PKA, contributing to a better understanding of various physiological and pathological conditions. -
PKA Antagonist
Rp-8-CPT-cAMPS sodium is a competitive antagonist of cAMP, specifically inhibiting the activation of protein kinase A (PKA) types I and II. It demonstrates preferential binding to site A of the regulatory subunit RI and site B of the regulatory subunit RII, making it a valuable tool for dissecting cAMP signaling pathways. This compound is widely utilized in research focused on intracellular signaling, pharmacology, and the role of PKA in various physiological processes. -
PKA Activator
Sp-8-CPT-cAMPS is a potent and selective activator of cAMP-dependent protein kinase A (PKA), specifically targeting PKA I and PKA II. This cAMP analog demonstrates a remarkable 153-fold selectivity for Site A of RI over Site A of RII and a 59-fold selectivity for Site B of RII over Site B of RI. Its ability to effectively modulate PKA activity makes it a valuable tool for research in signaling pathways and cellular responses associated with cAMP. -
PKA Substrate
H1-7 is a synthetic polypeptide designed as a substrate for protein kinase A (PKA). This compound effectively mimics histone H1 phosphorylation sites, allowing for the study of PKA-mediated phosphorylation processes. Its application is significant in understanding PKA signaling pathways and epigenetic modifications associated with histones in various biological contexts. -
PKA Antagonist
Rp-8-CPT-cAMPS is a potent antagonist of cAMP-dependent protein kinase A (PKA), inhibiting the activation of both PKA I and II. This cAMP analog selectively targets site A of the regulatory subunit type I over site A of type II, as well as site B of type II over site B of type I. Its ability to modulate PKA activity makes it a valuable tool for investigating downstream signaling pathways influenced by cAMP. Researchers can utilize Rp-8-CPT-cAMPS in studies focused on cellular responses and signal transduction mechanisms. -
PKA Inhibitor
GEM-231 is an 18mer antisense oligonucleotide that specifically targets the mRNA of the PKA-I (RIα regulatory subunit of cAMP-dependent protein kinase type I). This compound has demonstrated the ability to induce cell growth arrest, apoptosis, and differentiation across various cancer cell lines in vitro, as well as in tumor models in vivo. GEM-231 serves as a valuable tool for investigating PKA signaling pathways and their implications in cancer biology. -
PKA Agonist
8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that functions as a protein kinase A (PKA) agonist. By mimicking cAMP, it activates critical signaling pathways such as PKA and Epac, facilitating studies on heart-related conditions. This compound is particularly useful for investigating cardiac ischemia and reperfusion injury, providing valuable insights into these pathological processes. -
PKA Inhibitor
PKI (5-24), amide is a potent inhibitor of cAMP-dependent protein kinase A (PKA), derived from the active region of the heat-stable inhibitor protein. With an inhibition constant (Ki) of 2.3 nM, it effectively disrupts PKA signaling pathways. This reagent is valuable for research applications focusing on PKA-mediated cellular functions and signaling cascades in various biological contexts. -
J-PKA Inhibitor
Aplithianines A is a selective inhibitor of J-PKAcα, exhibiting an IC50 value of 1 μM, while also demonstrating inhibition of wild-type PKA with an IC50 of 84 nM. This compound exerts its inhibitory effects by competitively binding to the ATP pocket of J-PKAcα, thereby affecting its catalytic activity. Aplithianines A is valuable for research applications involving protein kinase signaling pathways and the study of PKA-related cellular processes. -
PKA Inhibitor
PKItide is a potent inhibitor of Protein Kinase A (PKA), exhibiting an IC50 of 0.2 μM for cAMP-dependent PKA. This compound effectively disrupts PKA signaling pathways, making it a valuable tool for studying cellular processes regulated by cAMP. Research applications include investigating the role of PKA in various physiological and pathological conditions, as well as exploring therapeutic strategies targeting PKA-related diseases. -
PKA Activator
8-CPT-6-Phe-cAMP is a potent activator of protein kinase A (PKA), functioning as an analogue of the signaling molecule cyclic adenosine monophosphate (cAMP). This compound is widely utilized in research to study PKA-mediated pathways and cellular responses related to various physiological processes. Its ability to effectively modulate PKA activity makes it an essential tool for investigating signal transduction mechanisms and pharmacological interventions. -
PKA I/II Antagonist
Rp-cAMPS is a potent antagonist of cyclic adenosine monophosphate (cAMP) that effectively inhibits the activation of protein kinase A (PKA) types I and II, exhibiting Ki values of 12.5 µM and 4.5 µM, respectively. This cAMP analog is resistant to hydrolysis by phosphodiesterases, making it suitable for research focused on cAMP signaling pathways. Rp-cAMPS is commonly used in studies investigating the regulatory role of PKA in various physiological processes and disease models. -
PKA Inhibitor
Rp-8-Br-cAMPS is a potent inhibitor of protein kinase A (PKA) that functions by occupying the cAMP binding sites on the regulatory subunits of PKA type I. This inhibition prevents the dissociation and activation of PKA, thereby modulating downstream signaling pathways. Rp-8-Br-cAMPS is particularly useful in research applications focused on tumor biology, retrovirus-induced immune deficiency, and the regulation of insulin secretion.
